GB9226832D0 - Pharmaceutical preparations for the treatment of psoriasis - Google Patents

Pharmaceutical preparations for the treatment of psoriasis

Info

Publication number
GB9226832D0
GB9226832D0 GB929226832A GB9226832A GB9226832D0 GB 9226832 D0 GB9226832 D0 GB 9226832D0 GB 929226832 A GB929226832 A GB 929226832A GB 9226832 A GB9226832 A GB 9226832A GB 9226832 D0 GB9226832 D0 GB 9226832D0
Authority
GB
United Kingdom
Prior art keywords
psoriasis
treatment
pharmaceutical preparations
preparations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB929226832A
Other versions
GB2273873A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Original Assignee
University of Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sheffield filed Critical University of Sheffield
Priority to GB9226832A priority Critical patent/GB2273873A/en
Publication of GB9226832D0 publication Critical patent/GB9226832D0/en
Publication of GB2273873A publication Critical patent/GB2273873A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB9226832A 1992-12-23 1992-12-23 Treatment of psoriasis Withdrawn GB2273873A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9226832A GB2273873A (en) 1992-12-23 1992-12-23 Treatment of psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9226832A GB2273873A (en) 1992-12-23 1992-12-23 Treatment of psoriasis

Publications (2)

Publication Number Publication Date
GB9226832D0 true GB9226832D0 (en) 1993-02-17
GB2273873A GB2273873A (en) 1994-07-06

Family

ID=10727120

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9226832A Withdrawn GB2273873A (en) 1992-12-23 1992-12-23 Treatment of psoriasis

Country Status (1)

Country Link
GB (1) GB2273873A (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
DE4407742C1 (en) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermal patch for treating tumours
US5556871A (en) * 1995-04-24 1996-09-17 President & Fellows Of Harvard College Method for treating epithelial precancerous lesions with topical inidazoles
ATE377418T1 (en) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES WITH TAMOXIFEN ANALOGUES
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
CO5271709A1 (en) * 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE AND TREATMENT OF AFFECTIONS RESPONDING TO STROGENS
EP1345618B1 (en) * 2000-12-28 2005-03-23 Switch Biotech Aktiengesellschaft Chlorzoxazone for the treatment of psoriasis
GB0710899D0 (en) * 2007-06-07 2007-07-18 Syntopix Ltd Formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3114824A1 (en) * 1980-05-07 1982-04-08 Gerhard Prof.Dr.med. 8500 Nürnberg Weber "USE OF A MEDICINE FOR THE TREATMENT OF PSORIASIS (psoriasis)"

Also Published As

Publication number Publication date
GB2273873A (en) 1994-07-06

Similar Documents

Publication Publication Date Title
US5281607B1 (en) Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB2188844B (en) Pharmaceutical composition for the treatment of psoriasis
HU9300536D0 (en) Compounds of medical effect
AU4048295A (en) Peptide medicaments for the treatment of disease
GB9226832D0 (en) Pharmaceutical preparations for the treatment of psoriasis
IL101410A0 (en) Formulation for the treatment of cancer
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
AU2806692A (en) Medicament for the treatment of anxiety
AU4220193A (en) Deazaaminopterins for treatment of inflammation
GB9103278D0 (en) Drug for the treatment of dermatitis
AU4081393A (en) Medicaments for the treatment of anxiety
IL93242A0 (en) Pharmaceutical preparation for the treatment of tonsillitis
ZA932450B (en) Drugs for the treatment of diabetes
HU9402816D0 (en) Medicament for the treatment of airways inflammation and airways hyperresponsiveness
PL308307A1 (en) 3-substituted 2-oxyindolo-1-carboxylamide pharmaceutical preparations
IL99236A0 (en) Pharmaceutical composition for the topical treatment of psoriasis
IL105690A0 (en) Pharmaceutical compositions for the treatment of arrhythmia
NZ255753A (en) Use of substituted azaspiranes for psoriasis treatment
AU4825993A (en) New compounds for use in the treatment of cancer
GB9201193D0 (en) Treatment of liquids
AU4119993A (en) Heteroaroyl-10-deazaaminopterins for treatment of inflammation
GB2266241B (en) Treatment of pastures
HU9200294D0 (en) Process for the production of medical preparations
HU913310D0 (en) Process for the production of medical preparations for treating psoreasis
GB9413939D0 (en) Pharmaceutical composition for the treatment of chronic skin ulcers

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)